![Mads Dalsgaard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Posizioni attive di Mads Dalsgaard
Società | Posizione | Inizio | Fine |
---|---|---|---|
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Direttore/Membro del Consiglio | 01/06/2018 | - |
Independent Dir/Board Member | 01/06/2018 | - |
Storia della carriera di Mads Dalsgaard
Statistiche
Distribuzione geografica
Spagna | 2 |
Posizioni
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Health Technology |
- Borsa valori
- Insiders
- Mads Dalsgaard
- Esperienza